Navigation Links
Cytel and Medelis Present an Educational Webinar April 7: Transforming Oncology Development with Adaptive Studies
Date:3/24/2011

CAMBRIDGE, Mass. and PHOENIX, March 24, 2011 /PRNewswire/ -- Cytel, a leading provider of adaptive clinical trial services and software, jointly announced with oncology-focused CRO Medelis, the opening of registration for their April 7 webinar "Transforming Oncology Development With Adaptive Studies".

Over 50% of confirmatory clinical studies today end in failure – a distressing reality, especially for oncologists and developers of cancer treatments. Fortunately, increasing use of validated adaptive designs is helping reverse this discouraging trend.

With their improved probability of successful outcome, adaptive trials are increasingly proposed and accepted by international regulatory agencies. Download the FDA's guidance at: www.fda.gov, search: "download adaptive guidance".

Bridging the gap between statistical innovations and clinical reality, the webinar program will educate all oncology treatment stakeholders: study sponsors, their investors, the medical community, and regulators. The webinar centers on the breakthrough adaptive Promising Zone "de-risking" strategy now accepted for pivotal phase 3 development studies.

The April 7 webinar speakers: noted oncology advisor Dr. John Grous from Medelis and Cytel President and Co-Founder Cyrus Mehta, PhD. Together, they'll examine two actual, adaptive confirmatory studies currently underway.

DownloadReferencePublicationsRecommended webinar references include the U.S. Food and Drug Administration's Adaptive Trials Guidance, providing biopharmaceutical study sponsors the established metrics to confidently utilize adaptive methods. The recent peer-reviewed publication Adaptive Increase in Sample Size when Interim Results are Promising documents the underlying Promising Zone statistical technique, adaptive Sample Size Re-estimation.

AbouttheSessionTransforming Oncology Development With Adaptive StudiesThursday, April 7th, 201111:00 AM – 12:00 PM EDTRegister free at: http://bit.ly/cytelwebinar AboutCytelCytel Inc. is a leading provider of clinical trial services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets.

Cytel pioneered the statistical and computational science of adaptive clinical trials and has designed more validated adaptive trials than any other service provider.

AboutMedelisMedelis is an oncology focused CRO with the depth of expertise and agility to

deliver accurate results quickly.

From our advisory board to our project managers and CRAs, Medelis offers deep experience in every facet of the oncology drug development process at all levels of our organization.


'/>"/>

SOURCE Cytel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Dr. Daniel Von Hoff presented with top genomics award from Scripps
2. Preview of oral presentations at the 1st IOF-ESCEO Pre-Clinical Symposium
3. Tip sheet: Caltech researchers presenting at AAAS
4. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
5. Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India
6. 23andMe presents top 10 most interesting genetic findings of 2010
7. Colossal fossil: Museums new whale skeleton represents decades of research
8. Portraits of the Mind author to present a visual history of the brain at public event in New York
9. Bioenergy III Conference: Present and New Perspectives on Biorefineries
10. Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
11. Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology: